PDCD1 and head and neck squamous cell carcinoma: Recently, nivolumab and the anti-PD-1 pembrolizumab showed a significant activity in patients with HNSCC who progressed on or after platinum-based regimens (6, 7); consequently, both the drugs have been approved by Food and Drug Administration (FDA) for platinum-refractory R/M-HNSCC.